New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 28, 2014
12:24 EDTPCYC, JNJFDA expands approved use of Imbruvica for chronic lymphocytic leukemia
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica to treat patients with chronic lymphocytic leukemia who carry a deletion in chromosome 17, which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. The FDA is also approving new labeling to reflect that Imbruvica’s clinical benefit in treating CLL has been verified. Imbruvica’s new use is being approved more than two months ahead of the product’s prescription drug user fee goal date of Oct. 7, the date the FDA was scheduled to complete review of the drug application. Imbruvica also received accelerated approval in November 2013 for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. Clinical studies to verify and describe Imbruvica’s clinical benefit in mantle cell lymphoma are ongoing. Imbruvica is being jointly developed and commercialized in the United States by Pharmacyclics (PCYC) and Janssen Biotech (JNJ).
News For PCYC;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 20, 2015
17:31 EDTJNJJ&J considering sale of Cordis with Cardinal the leading suitor, Bloomberg says
Subscribe for More Information
16:03 EDTJNJOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
07:23 EDTJNJAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
February 19, 2015
09:59 EDTPCYCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:59 EDTPCYCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Altisource Residential (RESI) upgraded to Neutral from Sell at Compass Point... Angie's List (ANGI) upgraded to Overweight from Equal-Weight at First Analysis... Barrick Gold (ABX) upgraded to Buy from Hold at TD Securities... British Land (BTLCY) upgraded to Buy from Hold at Societe Generale... Coach (COH) upgraded to Buy from Hold at Topeka... Fiat Chrysler (FCAU) upgraded to Outperform from Neutral at Exane BNP Paribas... Garmin (GRMN) upgraded at BofA/Merrill... Hologic (HOLX) upgraded to Buy from Hold at Canaccord... Iberdrola (IBDRY) upgraded to Neutral from Underweight at HSBC... KPN (KKPNY) upgraded to Neutral from Underperform at Exane BNP Paribas... Monster Worldwide (MWW) upgraded at Evercore ISI... Pharmacyclics (PCYC) upgraded to Buy from Neutral at Nomura... RPC, Inc. (RES) upgraded to Equal Weight from Underweight at Morgan Stanley... Sanofi (SNY) upgraded to Buy from Neutral at BofA/Merrill... Sasol (SSL) upgraded to Neutral from Underweight at HSBC... Tractor Supply (TSCO) upgraded at Oppenheimer... Valero (VLO) upgraded to Buy from Hold at Deutsche Bank... Weingarten Realty (WRI) upgraded to Neutral from Sell at UBS... Werner (WERN) upgraded on improving freight fundamentals at RBC Capital... diaDexus (DDXS) upgraded to Buy from Neutral at Ladenburg,
07:41 EDTPCYCPharmacyclics price target raised to $204 from $153 at Leerink
Subscribe for More Information
06:32 EDTPCYCPharmacyclics price target raised to $205 from $180 at Deutsche Bank
Subscribe for More Information
06:24 EDTPCYCPharmacyclics downgraded to Neutral from Overweight at JPMorgan
Subscribe for More Information
06:15 EDTPCYCPharmacyclics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
06:08 EDTPCYCPharmacyclics upgraded to Buy from Neutral at Nomura
Subscribe for More Information
February 18, 2015
16:46 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
16:06 EDTPCYCPharmacyclics reaffirms 2015 product revenue guidance
Subscribe for More Information
16:04 EDTPCYCPharmacyclics reports Q4 EPS 96c, consensus 76c
Subscribe for More Information
15:35 EDTPCYCNotable companies reporting after market close
Subscribe for More Information
12:36 EDTJNJAnalysts applaud cheaper than expected Boston Scientific settlement
Subscribe for More Information
12:31 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
07:41 EDTJNJSettlement 'a big win' for Boston Scientific, says Bernstein
Subscribe for More Information
07:12 EDTJNJBoston Scientific settlement should remove overhang, says Stifel
Subscribe for More Information
07:09 EDTJNJBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use